Geriatric
A new study found that more than one-third of patients aged older than 65 years do not receive...
Treosulfan demonstrated a significant improvement in EFS over RIC busulfan with a clinically meaningful benefit.
The approval was based on data from a trial that randomized patients with newly-diagnosed IDH1-mutated AML.
The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable ...
Older patients are at a significantly increased risk of immune-related AEs.
In a phase II prospective clinical trial, researchers evaluated the effectiveness of a personalized sequential therapy for ...
The use of hematopoietic stem cell transplantation (AHCT) is associated with excellent 2-year outcomes in multiple myeloma ...
Advertisement
Editorial Board
Sagar Lonial, MD, FACPSagar Lonial, MD, FACP, of the Winship Cancer Institute, is Editor-in-Chief of Blood Cancers Today.
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.